Clinical Trial Update: Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS II) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating whether dexmedetomidine-induced sleep can reduce delirium and related ICU neurological dysfunction is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Delirium

Drugs mentioned

• Dexmedetomidine (Dexmedetomidine)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Delirium | Phase 3 | Status: RECRUITING